ClinicalTrials.gg
Sign In
RecruitingNCT05544799Updated Feb 2, 2026

Case Studies of Patients Who Had Experienced Near Death Experience

An observational study in Near Death Experience, sponsored by Seoul National University Hospital. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-02-02.

Sponsored by Seoul National University Hospital · Observational

From the registry’s dates

  • Started Jan 2021; still recruiting 5 years 10 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
19 Years and older
Sex
All
01

Study summary

An prospective observational study to interview patients who had near death experiences among those who had received intensive care unit intervention during admission in hematology ward.

02

Conditions studied

  • Near Death Experience

Browse trials for

03

In context

Death

456 studies on the registry are indexed under Death; 86 are open to participants now.

This study's planned enrollment of 200 is below the median of 400 across 236 observational studies indexed under Death.

Browse Death studies →

Lead sponsor

Seoul National University Hospital is the lead sponsor of 1,900 studies on the registry; 274 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.

Browse Seoul National University Hospital studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with hematologic cancers who are in admission.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (≥19yrs) who are in admission in the Hematology ward of Seoul National University Hospital, and one of the following conditions.

    1. recovered after cardiopulomary resuscitation
    2. recovered after mechanical ventilator
    3. recovered after ICU care
    4. recovered after emergent operation
    5. recovered after Shock, coma, altered mentality
    6. Other medical conditions approaching death

Exclusion criteria

Exclusion Criteria:

  1. Those who do not agree to participate this study
  2. Those who can not be interviewed due to insufficient recovery from critical medical problems
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Interventions

  • OtherNo intervention

    No intervension

06

What researchers measure

Primary outcomes

  1. Incidence of near death experience (NDE)

    Incidence of case with NDE scale ≥7 point

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Dec 2027, 83 months after the start.

Of 84 non-industry observational studies under Death, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 245. This study's planned 83 months is above that.

Counting every sponsor, half of 87 studies reached it within 60 months; a quarter within 23 and three quarters within 245.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2022
First posted
Sep 16, 2022
StartActual
Jan 3, 2021
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2031
Last update
Feb 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05544799
Lead sponsor
Seoul National University Hospital
Responsible party
Dong-Yeop Shin (Professor, Seoul National University Hospital) — Principal investigator
First posted
Sep 16, 2022
Start date
Jan 3, 2021
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Feb 2, 2026

Study contacts

Dong-Yeop Shin, MD, PhD
Contact
stephano.dyshin@gmail.com
+82220727209
Dong-Yeop Shin, MD, PhD
principal investigator · Department of Internal Medicine, Seoul National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Death →

Other studies from this sponsor

Seoul National University Hospital →

Start the discussion